PCC Dosing for Warfarin Reversal
For warfarin-associated bleeding or urgent procedures, administer 4-factor PCC at weight-based doses of 25 units/kg for INR 2-<4,35 units/kg for INR 4-6, and 50 units/kg for INR >6, with a maximum dose capped at 100 kg body weight, always combined with 10 mg intravenous vitamin K. 1, 2
INR-Based Dosing Algorithm
The most current guidelines and FDA labeling provide clear weight and INR-based dosing:
- INR 2 to <4: 25 units/kg (maximum 2,500 units)
- INR 4-6: 35 units/kg (maximum 3,500 units)
- INR >6: 50 units/kg (maximum 5,000 units)
For patients >100 kg, do not exceed the maximum dose for each INR category 2. The 2025 French guidelines support similar dosing, recommending 25 units/kg when INR is unavailable and urgent reversal is needed 3.
Critical Timing Considerations
Always administer vitamin K concurrently (10 mg IV or PO) to maintain factor levels once PCC effects diminish 1, 3. The 2020 ACC guidelines specify vitamin K dosing, while 2025 French guidelines emphasize 10 mg for severe bleeding 3.
Check INR within 30 minutes post-administration to confirm adequate reversal 3. Most patients achieve INR ≤1.5 within 30 minutes, though the relationship between specific INR values and clinical hemostasis remains incompletely defined 2.
Special Situations
Intracranial Hemorrhage
For intracranial bleeding, target INR <1.2 rather than <1.5 3. The 2020 ACC recommends fixed-dose alternatives for ICH: 1,500 units regardless of INR 1.
When INR Unavailable
If urgent reversal is needed before INR results: administer 25 units/kg PCC plus 5 mg IV vitamin K, proceed with the intervention, then check INR within 30 minutes 3. Consider supplemental dosing if target not achieved.
Fixed-Dose Alternative
The ACC guidelines mention a simplified fixed-dose option: 1,000 units for non-intracranial major bleeding or 1,500 units for ICH 1. However, this approach may be less effective than weight-based dosing, particularly for patients with baseline INR ≥5 4, 5.
Important Caveats
Repeat dosing is not recommended as safety and effectiveness have not been established 2. If INR remains elevated at 30 minutes, consider supplemental dosing per manufacturer recommendations rather than full repeat doses 3.
Monitor for thromboembolic complications, which represent the primary safety concern. Patients with thromboembolic events in the prior 3 months may not be suitable candidates 2. The risk-benefit calculation must weigh bleeding severity against thrombotic risk, particularly in patients with underlying prothrombotic conditions 1.
Recheck INR at 6-8 hours and 24 hours after initial reversal to guide additional vitamin K administration, as PCC effects may wane while warfarin remains active 3.
Evidence Quality Note
The weight-based dosing strategy is supported by the highest quality evidence: 2025 French multi-society guidelines 3, 2020 ACC expert consensus 1, and current FDA labeling 2. Research demonstrates individualized dosing based on INR and weight achieves target INR more effectively than fixed dosing (89% vs 43% success rate) 6. However, doses of 500 units are consistently inadequate for INR >2.5 4, 5.